We recommend that you always use the latest version of your browser.

NevroforskSør

Research on the nervous system and diseases of the nervous system

nevroforsk sør.jpg

Genetics of amyotrophic lateral sclerosis (ALS) in Norway

Based in Telemark

We contribute to patient recruitment/data collection

Multicenter study to map the genetic profile of ALS patients

More information (external website)​

Local contact: Unn Ljøstad

​NO-A LS Extension Study

Based in Haukeland/UiB

We contribute to patient recruitment/data collection

To evaluate safety and make nicotinamide/pterostilbene supplements available for compassionate use for ALS patients from Agder who have completed the NO-ALS study

More information (external website)

Local contacts: Unn Ljøstad and Kristine Forselv

NoCVT: Incidence, diagnosis, and treatment of cerebral venous thrombosis in Norway

Based at Ahus

We will contribute to patient recruitment/data collection

Multicenter study

More information (external website)

Local contact: Unn Ljøstad

TWIST: Tenecteplase in Wake-up Ischaemic Stroke Trial

Based at the University Hospital of North Norway.

A multinational and cross-regional project

One PhD student from SSHF

  1. Can tenecteplase given within 4.5 hours of waking improve functional outcomes at 6 months? (a randomized controlled study of thrombolytic treatment with tenecteplase in patients with acute ischemic stroke that occurred before waking)
  2. Can CT findings identify patients who benefit more from this treatment?

PhD student: Mary-Helen Søyland

Supervisors: Arnstein Tveiten ++

Funding: Research Council of Norway, Norwegian Women's Public Health Association, Helse Nord and ?

More information (external website)

 

COVITA

Based in Telemark

We contribute to patient recruitment/data collection

Follows SARS-CoV-2 IgG antibody levels over time to learn more about immunity, and maps long-term symptoms

Local data collector: Randi Eikeland

More information (external website)

NevroCovid

Based at OUS

We contribute to patient recruitment/data collection

Investigates the prevalence, symptoms, and signs of neurological manifestations of COVID-19

Local data collector: Randi Eikeland

More information (external website)

BorrSci: Lyme borreliosis; a scientific approach to reduce diagnostic and therapeutic uncertainties (BorrSci)

An interdisciplinary and cross-regional project led by Sørlandet Hospital, consisting of 5 work packages;

1. Epidemiology, clinical characteristics, and laboratory findings in chronic Lyme borreliosis

2. Comparison of 2- and 6-week doxycycline treatment for neuroborreliosis, a randomized, double-blind, placebo-controlled, multicenter study

3. Establishment of a biobank for tick-borne diseases

4. Biomarkers in neuroborreliosis (immunology, genetics, MRI)

5. Dissemination of results and knowledge about neuroborreliosis.

Number of planned PhDs: 5 (3 at SSHF)

Funding: The regional health authorities through the Research Council of Norway.

Local PhD candidates

Neurologist: Anne Marit Solheim. Supervisors: Unn Ljøstad and Åse Mygland

Neuropsychologist: Silje Andreassen. Supervisors: Randi Eikeland ++

Radiologist: Elisabeth Lindland. Supervisors: Åslaug Rudjord Lorentzen ++

More information (external website)

NeoPropp: Neoehrlichiosis in patients with blood clots of unknown cause

A single-centre study at SSHF that will investigate the prevalence of positive PCR for neoehrlichiosis in blood samples from patients admitted with cerebral infarction, DVT and pulmonary embolism without any other known cause.

Neurology contact person: Benedicte Isefjær

NOTES Tick-borne encephalitis (TBE)

Based in Telemark.

We contribute by recruiting patients/collecting data.

  1. Description of acute illness in the cohort in Norway (2018 and 2019).
  2. What are the long-term effects? Examination with neuropsychological testing 24–36 months after the infection.
  3. Follow-up of patients to assess lasting immunity after infection. This is a project in collaboration with FHI and is also in its early stages.

Local data collectors: Åslaug Rudjord Lorentzen and Randi Eikeland

Strength training to reduce headaches – a pilot study

A prospective pilot study at SSHF that will investigate whether strength training can reduce headaches in patients with chronic migraine and possibly concomitant tension headaches and muscular neck pain. Use of an app for follow-up.

Responsible: Magne Bøe and Kristine Forselv

Funding: ?

Who can participate?

If you have MS and have received stem cell treatment abroad, can you participate in the study?

If you are registered in the MS Registry, a common link for study participation will be sent to you. If you have not received the invitation (sent out on 6 November).

Follow this link to take part in the study:https://nettskjema.no/a/samtykke-safe-ms

Contact information:Stine Schikora-Rustad (stirus@sshf.no)

Lege Stine Schikora-Rustad
Stine Schikora-Rustad

Project manager: Åslaug Rudjord Lorentzen

About the study:
The main aim of this study is to generate new knowledge about the safety and efficacy of autologous haematopoietic stem cell transplantation (AHSCT) as a treatment for multiple sclerosis (MS), and to investigate which groups benefit most from the treatment. This will be done by collecting information from several different registries and asking participants to complete a questionnaire.

The PhD position is internally funded, with project support from the Norwegian MS Association

What the study involves:

* After signing the consent form, all participants will be asked to answer questions about stem cell treatment, as well as questions about quality of life and experiences.

*No clinical follow-up appointments or blood tests are planned as part of the study, but we will collect data from various registries: Antibiotic use – obtained from the Norwegian Prescription Database; hospital admissions – obtained from the Norwegian Patient Registry; MS diagnosis, MRI findings, relapses, EDSS, use of other MS medications after treatment – obtained from the MS Registry and/or patient records; socioeconomic status – obtained from Statistics Norway.

Four hypotheses have been formulated:

1) People with MS (pwMS) who have undergone AHSCT abroad have a socioeconomic status similar to that of pwMS who have not undergone AHSCT

2) After treatment, pwMS who have undergone AHSCT have the same degree of neurological disability, signs of disease activity, hospital admissions to specialist neurology departments and safety outcomes as matched pwMS who have not undergone AHSCT.

3) pwMS who have undergone AHSCT have the same degree of depression, fatigue, anxiety and quality of life as matched pwMS who have not undergone AHSCT

4) It is possible to identify predictors of better outcomes after AHSCT

 

Samtykke SAFE-MS_versjon1.2_200124.pdf

A multicentre, prospective, randomised, open-label study with a blinded endpoint comparing treatment with cladribine versus rituximab in people with MS.

Based at Oslo University Hospital/UiO.

We contribute by recruiting patients/collecting data (recruitment completed).

Funding: NOR-MS was initiated before funding was secured; later, it received open project funding from HSØ and the Research Council of Norway.

Local principal investigator: Åslaug Rudjord Lorentzen

Other local investigators: Ingvild J Leiknes, Stine Schikora-Rustad

Local study nurse: Siv Pettersen

Follow the link for more information:More information (external website)

A national study investigating vaccine responses in people with MS by measuring both antibody production (the so-called humoral immune response) and T-cell activation (the so-called cellular immune response).

The study is conducted in collaboration between Oslo University Hospital, Haukeland University Hospital, Akershus University Hospital, Sørlandet Hospital, the Norwegian MS Registry and Biobank, the Norwegian Institute of Public Health and the MS Association.

The study began as a local project at OUS/SSHF (NOR-MS VAX), but quickly expanded into a national study.

The study is still recruiting patients (follow the link below).

Local contributors: Åslaug Rudjord Lorentzen, Ingvild J Leiknes, Stine Schikora-Rustad.

Follow the link for more information:OUH - Nevrovax (ous-research.no)

A multicenter, prospective, randomized, blinded study comparing treatment with rituximab versus ocrelizumab in people with MS.

Based at Haukeland University Hospital/UiB.

We contribute by recruiting patients/collecting data (recruitment completed).

Funding: KLINBEFORSK

Local principal investigator: Åslaug Rudjord Lorentzen

Other local investigators: Ingvild J Leiknes

Local study nurse: Siv Pettersen

Follow the link for more information:More information (external website)

A prospective, multicenter safety study to evaluate the long-term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing-remitting MS.

We contribute by recruiting patients/collecting data.

Funding: Sanofi

Local investigator: Åse Mygland

Other local data collectors: Unn Ljøstad, Kristine JN Forselv

Local study nurse: Siv Pettersen

Effect of intravenous immunoglobulins on painful sensory neuropathy evaluated by aggregated N-of-one trial

PhD project planned to start during 2022: Evaluate the effect of IVIG on pain in sensory neuropathy using an N-of-one study design with individual randomized, double-blind, multiple crossover comparison of IVIG and placebo

Funding: Internally funded by SSHF

PhD candidate: Jon Marius Ørnes

Supervisors: Unn Ljøstad and Åse Mygland

ParkVest: The Parkinson’s Study in Western Norway and Aust-Agder

Based in Stavanger and Haukeland.

We contribute by recruiting patients/collecting data

A PhD candidate from SSHF is assessing functional ability and the prevalence of motor and non-motor problems in a group of newly diagnosed patients with Parkinson’s disease.

Funding?

PhD candidate: Solgunn Ongre

Supervisor: Karen Herlofson

More information (external website)

The NoPark study: Effect of nicotinamide riboside, a vitamin B3 analogue, in patients with Parkinson’s disease

Based at Haukeland

We contribute by recruiting patients/collecting data

Local investigator: Karen Herlofson

More information (external website)

Tuberous sclerosis: Online survey of patients with tuberous sclerosis in Norway in Dec-20 (treatment, 58 patients) and Dec-21 (follow-up, 48 patients). Ragnar Solhoff (SSHF), together with geneticist Ketil Heimdal, OUS. Supported by NK-SE through Ninan Benan (SSE) and NFTSC (patient association).


Stine Schikora-Rustad: SAFE-MS: Stem cell treatment abroad in Norwegian patients with multiple sclerosis.

Ivana Sapina: The Southern-Norway Post-Stroke Atrial Fibrillation Study.

Solgunn Ongre: ParkVest: Functional ability and prevalence of motor and non-motor problems in newly diagnosed patients with Parkinson’s disease.

Anne Marit Solheim: BorrSci: Comparison of 2- and 6-week doxycycline treatment for neuroborreliosis, a randomized, double-blind, placebo-controlled, multicenter study.

Mary-Helen Søyland TWIST: Tenecteplase in Wake-up Ischaemic Stroke Trial.

Jon Marius Ørnes: Effect of intravenous immunoglobulins on painful sensory neuropathy evaluated by aggregated N-of-one trial.

  • Unn Ljøstad, PhD
  • Randi Eikeland, PhD
  • Karen Herlofson, PhD
  • Pauline Do, neurologist
  • Ingvild Leiknes, neurologist
  • Åslaug Lorentzen, PhD
  • Åse Mygland, PhD
  • Harald Reiso, PhD
  • Stine Schikora-Rustad, PhD candidate
  • Anne Marit Solheim, PhD candidate
  • Mary-Helen Søyland, PhD candidate
  • Erik Thortveit, PhD
  • Arnstein Tveiten, PhD
  • Solgunn Ongre, PhD candidate
  • Siv Pettersen, specialist nurse
  • Jon Marius Ørnes, PhD candidate
  • Halvor Øygarden, PhD
  • Ivana Sapina, PhD candidate

Chair: Unn Ljøstad,Unn.Ljostad@sshf.no
Board members:
Randi Eikeland
Erik Thortveit
Siv Pettersen
Last updated 14.05.2024
TEST VERSION
Machine-translated copy of sshf.no for testing only. Not official information.